Login / Signup

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.

Mei QiuShu-Yan LiuJin-Song GuKai-Kai LiLing-Lin LiLiang-Liang Ding
Published in: Endocrine (2020)
Keyphrases
  • type diabetes
  • glycemic control
  • cardiovascular disease
  • insulin resistance
  • metabolic syndrome
  • skeletal muscle
  • weight loss